**Table1.** **Demographic details of the patients and controls. Values are either mean ± SD or n (%) and range.**

|  |  |
| --- | --- |
| Parameters | mean±SD or n (%) |
| Total patients (n=30) |
| Age (years), range | 9.57±5.20, (2-17) |
| Female/Male | 11 (36.7%)/19 (63.3%)  |
| aGvHD (Yes/No) | 11 (57.9%)/8 (42.1%)  |
| Total controls (n=100) |
| Age (years), range | 35.29±8.40, (20-35) |
| Female/Male | 64 (64.0%)/36 (36.0%) |

acute Graft versus Host Disease:aGvHD

**Table 2:** TGF-β (C/T codon 10) polymorphism in the patients and controls, IFN-γ rs2069705 (C/T) polymorphism in the patients and controls.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TGF-β** **(C/T codon 10)** | **Patients** | **Controls** | **OR** | **95%CI** | **Fisher’s** **p** |
| **Genotypes** | n:a 30 (%) | n:c 100 (%) |  |  |  |
| **T/T** | 56.7% | 48.0% | 1.417 | 0.622-3.223 | 0.532 |
| **T/C** | 40.0% | 43.0% | 0.883 | 0.384-2.029 | 0.835 |
| **C/C** | 3.3% | 9.0% | 0.348 | 0.042-2.871 | 0.452 |
| **HWEp** | 0.518 | 0.886 |  |  |  |
| **an= 30, cn= 100; OR (95%CI)** |
| Hardy-Weinberg Equilibrium: HWE; Odds ratio:OR; Confidential Interval:CI; p significance value is <0.05; Transforming growth factor*-*β (TGF-β); Interferon gamma (IFN-γ) |
| **IFN-γ (C/T)** | **Patient** | **Control** | **OR** | **95%CI** | **Fisher’s** **p** |
| **Genotypes** | n:a 30 (%) | n:c 100 (%) |  |  |  |
| **C/C** | 73.3% | 51.0% | 2.642 | 1.075-6.495 | **0.036** |
| **C/T** | 16.7% | 42.0% | 0.276 | 0.097-0.780 | **0.016** |
| **T/T** | 10.0% | 7.0% | 1.476 | 0.357-6.102 | 0.696 |
| **HWEp** | 0.015 | 0.676 |  |  |  |
| **an= 30, cn= 100; OR (95%CI)** |

Hardy-Weinberg Equilibrium: HWE; Odds ratio:OR; Confidential Interval:CI; p significance value is <0.05 Transforming growth factor*-*β (TGF-β); Interferon gamma (IFN-γ)

**Table 3:** The frequency of HLA-DRB1,-DRB3,4,5 alleles in the patient and control groups

|  |  |  |  |
| --- | --- | --- | --- |
| **HLA-DRB1 alleles and HLA-DRB3,4,5** | **Patient (n:30)** | **Control (n:100)** | **p**  |
| **\*01** | 10.8% |  6.5% | 0.341 |
| **\*03** | 5.0% | 11.0% | **0.042** |
| **\*04** | 20.0% | 18.0% | 0.690 |
| **\*07** | 8.3% | 9.5% | 0.886 |
| **\*08** | 0.0% | 1.5% | 0.999 |
| **\*09** | 1.6% | 0.5% | 0.362 |
| **\*10** | 2.6% | 2.0% | 0.756 |
| **\*11** | 10.0% | 21.5% | **0.032** |
| **\*12** | 0.0% | 1.5% | 0.899 |
| **\*13** | 13.3% | 11.0% | 0.702 |
| **\*14** | 10.0% | 7.0% | 0.341 |
| **\*15** | 11.7% | 4.5% | **0.004** |
| **\*16** | 6.7% | 4.5% | 0.376 |
| **DRB5 (DR51)** | 18.4% | 10.0% | **0.054** |
| **DRB3 (DR52)** | 29.9% | 28.0% | 0.681 |
| **DRB4 (DR53)** | 38.3% | 52.0% | 0.248 |

Human Leukokcyte Antigen:HLA; DRB5 (DR51)(\*03,\*11,\*12,\*13,\*14); DRB3 (DR52)(\*15,\*16); DRB4 (DR53)(\*04,\*07,\*09)

**Table 4:** Association of IFN-γrs 2069705 (C/T) and TGF-β (C/T codon 10) genotypes between the subjects with and without aGvHD

|  |  |  |  |
| --- | --- | --- | --- |
| **IFN-γ rs 2069705 (C/T)** | **with aGvHD** **(n:8) %** | **without aGvHD****No (n:11) %** | **Fisher’s** **p**  |
| **C/C** | 62.5% | 45.5% | 0.177 |
| **C/T** | 25.0% | 36.3% | **0.044** |
| **T/T** | 12.5% | 18.2% | 0.421 |
| **TGF-β (C/T codon 10)** | **with aGvHD** **(n:8) %** | **without aGvHD****No (n:11) %** | **Fisher’s** **p** |
| **T/T** | 50.0% | 45.4% | 0.719 |
| **C/T** | 37.5% | 36.4% | 0.948 |
| **C/C** | 12.5% | 18.2% | 0.421 |

acute Graft versus Host Disease:aGvHD; Transforming growth factor*-*β (TGF-β); Interferon-gamm (IFN-γ)